Sg3 Management, LLC Mirati Therapeutics, Inc. Put Options Transaction History

Sg3 Management, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $230,202 - $341,838	-6,300 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $53,651 - $128,206	-1,300 Reduced 20.63%	5,000 $226,000
Q3 2022 May 15, 2023	BUY	$59.5 - $86.7 $77,350 - $112,710	1,300 Added 26.0%	6,300 $439,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $374,850 - $546,210	6,300 New	6,300 $440,000
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $180,135 - $408,066	-4,600 Closed	0 $0

Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $348,771 - $694,462	4,600 New	4,600 $378,000
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $907,200 - $1.13 Million	-6,300 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $190,703 - $265,932	-1,200 Reduced 16.0%	6,300 $1.08 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $405,125 - $600,675	-2,500 Reduced 25.0%	7,500 $1.65 Million
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $1.13 Million - $1.67 Million	10,000 New	10,000 $1.66 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.